Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16
May 11, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
DALLAS, May 11, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy
May 10, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
DALLAS, May 10, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)
May 03, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
Clinical efficacy data for TSHA-120 provide quantitative evidence of long-term durability across all therapeutic dose cohorts with a 10-point improvement in mean change in MFM32 by Year 3 compared to...
Taysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and the ASCEND National Summit
April 25, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
DALLAS, April 25, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
April 18, 2022 08:00 ET
|
Taysha Gene Therapies, Inc.
Chief Executive Officer, Chief Technical Officer, Chief Medical Officer and Head of Research and Development and Senior Vice President of Manufacturing to participate in a panel discussion at the...